SUBSCRIBE
SUBSCRIBE

Michelle Brugioni

Windtree Therapeutics CEO Craig Fraser_Windtree Th
Business
Esperion and Otsuka Team Up for Cardiovascular Drug Development and Commercialization in Japan
The collaboration for development and commercialization combines Esperion’s knowledge in lipid management and Otsuka’s extensive cardiovascular drug advancement and marketing in Japan.
April 21, 2020
 · 
2 min read
 · 
Michelle Brugioni
Drug Development
Vir Shares Findings from Phase 1/2 Trial for VIR-2218 in Hepatitis B Virus
Data from the ongoing Phase II trial, as well as results from the Phase I trial of VR-2218, was released during a live webcast presentation on Wednesday.
April 16, 2020
 · 
2 min read
 · 
Michelle Brugioni
Business
Ori Biotech and Achilles Therapeutics Partnering to Assess Novel CGT Manufacturing
“It is always great to work with the forward-thinking leaders in cell and gene therapy, like Achilles, who are focused on innovating across the board, not just clinically and scientifically but also technologically. We see huge potential for the future of this partnership,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech.
April 15, 2020
 · 
2 min read
 · 
Michelle Brugioni
Lone Star Bio
Study Shows Snake Venom Can Help Uncover Detailed Shape of Critical Protein in Muscle Contractions
The protein, called a nicotinic receptor, has been a challenge to study since it sits in the cell’s membrane.
April 14, 2020
 · 
2 min read
 · 
Michelle Brugioni
Study Shows Cancer Therapy Drug Could Stop or Reverse Damage to Kidneys Caused by Lupus Nephritis
A new study shows a cancer therapy drug may reverse the effects of lupus nephritis in patients with systemic lupus erythematosus (SLE, or lupus), an autoimmune disease.
April 10, 2020
 · 
1 min read
 · 
Michelle Brugioni
Study Shows Possible Alternative Treatment for High-Grade Glioma Tumors in Infants
“It’s especially cruel when cancer affects such small children, so it is encouraging that this study offers some hope for very young patients and their families,” said Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London.
April 7, 2020
 · 
3 min read
 · 
Michelle Brugioni
New Study Shows Possible Alternative Treatment for Unique Infant Tumors
The study reveals that brain tumors in babies are molecularly unique and could be candidates for targeted treatments.
April 3, 2020
 · 
3 min read
 · 
Michelle Brugioni
Business
Evox and Takeda Partner for Multi-Target Collaboration in Rare Diseases
The two companies plan to focus their efforts on targeting several rare diseases.
March 27, 2020
 · 
2 min read
 · 
Michelle Brugioni
Business
Vycellix and Avectas Join Forces to Address Cell-Based Therapy Limitations
Specifically, they will be looking at ways to improve processes by speeding up and reducing the cost of manufacturing.
March 26, 2020
 · 
2 min read
 · 
Michelle Brugioni
BioMidwest
Study Shows Development of Young Cells Could be New Option in Cancer Care
Washington University School of Medicine in St. Louis released a new study about the effectiveness of immunotherapy based on the age of the cells used.
March 25, 2020
 · 
2 min read
 · 
Michelle Brugioni
Business
Circle Pharma Raises $45 Million in Series B Financing to Advance Pipeline
“We are delighted to have these premier life science investors supporting our Series B financing,” said David J. Earp, Circle’s President and CEO.
March 20, 2020
 · 
2 min read
 · 
Michelle Brugioni
Business
Bristol Myers Squibb Announces Elizabeth Mily as New Executive Vice President, Strategy & Business Development
Mily will be leading the company strategy and all business development activities. This includes overseeing strategic partnerships, mergers and acquisitions, etc.
March 20, 2020
 · 
2 min read
 · 
Michelle Brugioni
New Strategy Blocking Enzymes May Decrease Risk of Tumor Growth
The new research showed that by blocking enzymes in the PIP2 recycling series, the series that turns PIP2 into inositol triphosphate and diacylglycerol and back to PIP2, they can stop angiogenesis (growth of new blood vessels).
March 19, 2020
 · 
1 min read
 · 
Michelle Brugioni
Drug Development
Findings Reveal Lack of Participants in Critical Research is Caused by Fear
Researchers found fear of testing new treatments and possible side effects were common denominators among patients.
March 17, 2020
 · 
2 min read
 · 
Michelle Brugioni
Genetown
Vertex Donates $500,000 to Partners Healthcare Amid COVID-19 Outbreak
The $500,000 gift was in response to the COVID-19 outbreak and a need for more support, testing capacity and advancements.
March 16, 2020
 · 
1 min read
 · 
Michelle Brugioni
Load More